With the recent discovery of recurrent mutations in the TERT promoter in melanoma, identification of other somatic causal promoter mutations is of considerable interest. Yet, the impact of sequence variation on the regulatory potential of gene promoters has not been systematically evaluated. This study assesses the impact of promoter mutations on promoter activity in the whole-genome sequenced malignant melanoma cell line COLO-829.
Implications: Genomic-based screening within gene promoter regions suggests that functional cis-regulatory mutations may be common in melanoma genomes, highlighting the need to examine their role in tumorigenesis.
Introduction
Cancers develop when certain somatic mutations are acquired by individual cells (1) .
However, most tumours harbour a number of different genetic and epigenetic aberrations (2, 3) . This means that identifying all driver mutations, and distinguishing them from passenger mutations, remains a major challenge (4, 5) . This problem is exacerbated in the non-coding genome, as a lack of selective pressure in these regions contributes to the acquisition of higher numbers of mutations. In the past, research into cancer driver mutations has typically focused on protein-coding mutations, as the functional consequence of non-coding mutations is difficult to determine. Furthermore, availability of datasets required for analysis of noncoding mutations has been limited. However, recurrent mutations in the TERT promoter were recently identified in melanoma and other cancers (6, 7) .
The TERT promoter mutations were the first recurrent cis-regulatory somatic point mutations identified in cancer that alter gene expression (6) . These mutations drive cancer by generating a transcription factor binding motif for E-twenty-six (ETS) transcription factors, with corresponding increases in promoter activity and expression of TERT (6) . Remarkably, mutations at the promoter of TERT are found in as many as 85% of metastatic melanomas and are also found at high frequency in many other cancers including glioblastoma (62%) and bladder cancer (59%) (7) .
With advances in sequencing technology (8) (9) (10) (11) , whole cancer genomes are being sequenced at a rapid pace and hundreds of sequenced samples are available for analysis from The Cancer Genome Atlas (TCGA), the Wellcome Trust Sanger Institute Cancer Genome Project and the International Cancer Genome Consortium (12) . This has led to a number of studies that have focused on mapping the cis-regulatory mutational landscape across cancers (13, 14) . These analyses have primarily used recurrence to determine those mutations with potential driver roles in cancer (13, 14) . However, while numerous recurrent cis-regulatory mutations have been identified, thus far, only a single promoter mutation in addition to the TERT promoter mutations, in the promoter of the SDHD gene, has been linked to changes in gene expression (13) . Nevertheless, from these studies, it is evident that mutations at promoters can be found in many cancers. It appears that promoter mutations may even be more prevalent in melanomas than other cancers. For example, one recent study analysing mutations within 500 bp of a transcription start site (TSS) that were recurrent in 5 or more cancer samples, found that 78% of those mutations identified were from melanomas (14) . In this study, we combine computational and experimental approaches to comprehensively survey the landscape of somatic promoter mutations in the genome of the malignant melanoma cell-line COLO-829 (19) . By using a whole-genome sequenced cell-line, we have been able to adopt an unbiased approach and experimentally assess the functional consequence of promoter mutations in a cell-specific manner. We have identified that there are multiple mutations that perturb promoter activity in the COLO-829 cell-line. In doing so, we have identified a mutation in the promoter of NDUFB9 which is recurrent in cutaneous melanomas, highlighting the need for further investigation of promoter mutations in melanoma development.
Materials and Methods
Further details of materials and methods are supplied in supplementary methods.
Mutation calls
The mutation calls used to identify putative somatic promoter mutations in the COLO-829 malignant melanoma cell-line were obtained from the COSMIC database (19) (20) (21) .
In addition, mutations were called in 34 whole-genome sequenced metastatic skin cutaneous melanoma tumour and matched normal samples from TCGA using the Strelka pipeline (22) .
For 432 whole-exome sequenced cutaneous melanoma samples, data was obtained from TCGA, and base calls were determined at specified sites using SAMtools mpileup (23) . Figure 1a . Putative promoter mutations were identified as those within these regions (26) and within +/-1 kB of a TSS as determined by RefSeq gene annotations (27) .
Identification of candidate COLO-829 promoter mutations

Mutation analysis
MutSigCV data (28) was plotted in Figure 2 , by the frequency of each given measure of expression, replication time and non-coding mutation count. The relevant values corresponding to each of the COLO-829 promoter mutations were also plotted.
For each COLO-829 promoter mutation identified, conservation was determined using the phastCons score (29) for the mutation itself, a 15 bp flanking region (mutation +/-7 bp) and the DHS peak in which the mutation lies. Transcription factor motifs created or removed by each mutation were identified by use of the OncoCis tool (15), which utilises transcription factor motifs from the JASPAR database (30) .
Reporter assays
Wild-type and mutant DHS regions flanking each COLO-829 putative promoter mutation were amplified by polymerase chain reaction (PCR) from COLO-829 melanoma and HCC1143 breast cancer genomic DNA (Table S3; see Table S6 for PCR primers). To produce reporter constructs, regions were cloned upstream of the firefly luciferase gene in the promoter-less vector pGL2 Basic (Promega Corporation, WI, USA). Any single nucleotide polymorphisms (SNPs) in reporter constructs are recorded in Table S5 . were co-transfected into COLO-829 cells using Lipofectamine 2000 (Life Technologies, VIC, Australia), with reporter gene activity measured after 48 hours. All constructs were tested in quadruplicate in at least two independent experiments. A mutant promoter region was determined to have different activity from wild-type in cases in which the mutant produced altered promoter activity in the same direction over three or more experiments, and was statistically significant at least once (p<0.05, by unpaired t-test).
NDUFB9 promoter mutation and gene analysis
RNA-sequencing data for metastatic melanomas were obtained from TCGA and plotted in Figure 4c . Mutant and wild-type samples were identified by determining mutation calls from whole-exome sequencing data using SAMtools mpileup (23).
Co-occurrence (see Figure 4d ) was analysed among samples with and without the NDUFB9 promoter mutation, using samples and mutation calls from TCGA. Samples were deemed mutated if they had at least one non-silent protein-coding mutation in each gene from a list of commonly mutated melanoma genes used in previous research (32) . Significant associations (p<0.05) were calculated by a two-tailed Fisher's exact test, using counts of mutations in each designated gene for NDFUB9 wild-type and mutant promoter groupings.
Results and Discussion
Identification of promoter mutations in the COLO-829 melanoma genome Somatic mutation calls for the whole-genome sequenced COLO-829 cell-line (19) were first obtained from the Catalogue of Somatic Mutations in Cancer (COSMIC) database (20, 21) . In total, there were 32,901 unique somatic mutation sites (Figure 1a) . We developed Figure 1a) . To identify promoters, we overlapped mutation calls with DHS and H3K4me3 peaks as shown in Figure 1a , and determined which of those were within +/-1 kB of a RefSeq annotated TSS (27) . We chose to prioritise mutations within DHS peaks as these regions represent the most active regulatory regions.
The use of H3K4me3 data further enabled us to define cell type specific gene promoters. We found 26,035 COLO-829 DHS peaks to overlap a melanocyte H3K4me3 region ( Figure 1a ), with 59% of those being within +/-1 kB of a TSS ( Figure S1a ). Supporting our method of genome-wide promoter designation, genes with a promoter DHS peak in COLO-829 were found to be significantly more highly expressed than those without (p<0.0001, by unpaired ttest; Figure S1b ). To further support our methodology, when using Fantom5 (33) TSS annotations rather than RefSeq (27) annotations for TSS, we found there to be a high degree of overlap in the mutations identified ( Figure S1c ).
Using COLO-829 somatic mutation calls, we found 31 mutations that were within a COLO-829 DHS and melanocyte H3K4me3 peak. We performed a bootstrap analysis to determine the likelihood of finding this number of putative promoter mutations in the COLO-829 cell-line. This analysis ( Figure S1d ) revealed that the number of promoter mutations in COLO-829 (n=31) was significantly lower than the median number of mutations (n=41) which occurred at random in 1,000 iterations. This finding is consistent with previous research which indicates that somatic mutation density is reduced in regulatory DNA due to the accessibility of DHS regions to global genome repair machinery (34) .
We found that 23 of the 31 COLO-829 mutations were within +/-1 kb of a TSS, and we therefore selected these for further analysis ( Figure 1a , Table S1 ). Of these 23 mutations, five mapped to putative bidirectional promoters, providing a total of 28 candidate associated 
Analysis of genomic context of COLO-829 promoter mutations
To determine whether the 23 promoter mutations occur in regions of the genome that are generally mutated more frequently, we compared the expression, replication time and region mutation frequency of the COLO-829 promoter mutations against genomic rates generated by MutSigCV (28) . Results indicate that the majority of COLO-829 promoter mutations lie within highly expressed regions with short replication times (Figures 2a and   2b ). The mutations were also within regions that are amongst the most common non-coding mutation rates in the genome (Figure 2c ). This suggests that the promoter mutations are not enriched within highly variable genomic regions, which are typically late replicating and contain lowly expressed genes (28) .
Finally, in order to establish whether COLO-829 is similar to, and therefore broadly indicative of, metastatic melanoma samples, we analysed mutations within 34 whole-genome sequenced melanoma datasets from TCGA. We found that the number of promoter mutations ranged from 1 to 548 mutations per sample (median 80, Table S2 ). When normalised to the total number of mutations across the genome, we found the promoter mutation rate of COLO-829 was slightly lower than the median rate across all melanomas (0.0007 versus 0.0013 promoter mutations/total mutation). This suggests that while promoter mutations are generally even more frequent in melanoma samples compared with COLO-829, the findings from our study should still be broadly representative of melanoma samples. However, further research will need to firmly establish whether the frequency of functional promoter mutations found in COLO-829 is truly representative of melanoma genomes more generally. To eliminate false-positive mutation calls, we validated each putative promoter mutation by interrogating COLO-829 whole-genome as well as Sanger sequencing data from PCR amplified regions. Of 23 putative promoter mutations, we could validate 20, with these being within +/-1 kB of 25 different genes (Table 1) . We next performed a series of analyses to annotate each COLO-829 putative promoter mutation and infer their functional impact.
Annotation and validation of promoter mutations in COLO-829
Half of the 20 validated COLO-829 putative promoter mutations were deemed to be highly conserved, as they lie within a 15 bp region (mutation +/-7 bp) with a greater average PhastCons conservation score (29) than the surrounding COLO-829 DHS region (Table 1) .
Furthermore, 19 of the 20 validated mutations alter transcription factor motifs (Table 1) Having identified 20 validated mutations with the potential to alter promoter activity, the functional consequence of each mutation was tested using reporter assays in COLO-829 cells. Wild-type and mutant promoter regions were isolated for 23 out of 25 genes (Table S3 ).
For potential bi-directional promoters, regions were cloned in both directions and promoter activity assessed independently. As shown in Figure 3 , we identified four gene candidates by reporter assays in which the mutant plasmid construct had significantly altered promoter activity from wild-type (p<0.05, by unpaired t-test). These genes are HIST1H3H, NDUFB9, PSMC6 and SPSB3, with each harbouring a single promoter mutation in COLO-829 (Table   1 ). When applying a Benjamini and Hochberg False Discovery Rate multiple testing correction, all mutations except for the PSMC6 putative promoter mutation remain significant.
We hypothesised that single-base mutations in highly conserved regions which altered binding motifs, would be the most likely to lead to a change in expression when compared to wild-type. However, these analyses did not accurately predict which mutations would have 
functional consequences as subsequently demonstrated by altered promoter activity in reporter assays. Of the nine mutations which altered transcription factor binding motifs and were deemed to be highly conserved (Table 1) , only two altered promoter activity in reporter assays (those in the NDUFB9 and SPSB3 promoters). Two mutations, which altered promoter activity in reporter assays (those in the HIST1H3H and PSMC6 promoters), were not highly conserved (Table 1 ) and thus had not been predicted to be functional. This suggests that conservation may not be a sufficient predictor of whether a mutated base has functional consequences in vivo or in vitro. In fact, the TERT promoter mutations also do not fall within conserved regions (15), lending support to this hypothesis.
To establish whether other methods for assessing non-coding mutations were useful in predicting functional mutations, we scored the mutations using the recently published tools:
RegulomeDB (17), Funseq2 (16) and FATHMM-MKL (18) ( Table 1) . We found that the mutations associated with PSMC6 and NDUFB9 generally had amongst the highest scores across the three tools. A comparison of the three tools using a receiver-operator curve ( Figure   S2 ) showed that Funseq2 (16) had the best performance, followed by FATHMM-MKL (18) and RegulomeDB (17) in terms of using their respective scores to identify functional variants.
However, it was evident that across all three tools, many mutations found not to perturb promoter activity also had relatively high scores. This means that while the tools were generally quite sensitive in detecting functional promoter mutations, they are not particularly specific. It is important to note however, that the mutations selected for analysis here are only those which were already found to fall within a promoter region of a gene. The majority of mutations, if not all, would fall within ENCODE DHS regions and transcription factor binding sites. Thus, most of the mutations would have a high background score relative to all mutations across a genome. Therefore, the specificity of the tools considered here is likely to be much higher when applied in genome-wide analysis of mutations. 
It is vital to account for tissue specificity when identifying active promoter regions (15). In our analysis, we utilised matched-tumour COLO-829 DNase-seq data to identify putative promoter mutations. Such a methodology prioritises the identification of mutations in existing and novel DHS regions. However, our analysis is limited in its ability to identify mutations which remove a DHS site. To explore this, we conducted an analysis using melanocyte DNase-seq data in place of COLO-829 DNase-seq data. Our results are summarised in Figure S3a , where we found that the majority of mutations, including the NDUFB9 putative promoter mutation, could be identified with both COLO-829 and melanocyte data (n=17). However, n=6 mutations were identified from COLO-829 DNaseseq only, and n=4 mutations were identified from melanocyte DNase-seq only. To determine whether the four mutations present only from melanocyte DNase-seq could potentially have removed a COLO-829 DHS region and might warrant further analysis, we analysed RNAsequencing data from melanoma cell-lines in the Cancer Cell Line Encyclopedia (CCLE) (35) . We found that all associated genes were expressed in COLO-829 at similar levels as in other melanoma cell-lines ( Figure S3b ). While these mutations still warrant further analysis in order to determine whether they may yet impact on promoter activity, this finding suggests that the mutations are unlikely to be responsible for the complete removal of a DHS region in the COLO-829 cell-line and a corresponding loss of expression of the associated gene.
Instead, there is some evidence that the DHS peak may have shifted in COLO-829, possibly due to the presence of the promoter mutation ( Figure S3c ), but this would need further investigation. Additionally, we also performed an analysis using DNase-seq and H3K4me3
ChIP-seq data from other common cell-lines ( Figure S3d and S3e). We found that as many as 48% (n=11, from GM12878 lymphoblastoid cells; Figure S3d and H3K4me3 ChIP-seq data from other cell-lines. We performed an analysis of putative promoter mutations in DHS peaks (150 bp) which were not within 500 bp (+/-175 bp) of a COLO-829 DHS peak using data from different cell-lines ( Figure S3e ). We found a handful (n=8) of additional mutations, many of which were unique to a single cell-line. With the exception of a single mutation (chr7:75,834,729 at ZNF717; Figure S3e ), all of these COLO-829 mutations fell outside of DHS regions from both COLO-829 and melanocytes. This means that it is unlikely that these mutations would be functional in either cell type and so do not warrant further testing. These results highlight the importance of using matched molecular data, whilst also potentially incorporating unmatched data to answer more targeted research questions.
Evaluating the significance of the recurrent NDUFB9 promoter mutation
It is interesting to note that somatic promoter mutations with functional consequences were reasonably prevalent -occurring in 4/23 (17.4%) promoter regions tested in COLO-829 ( Figure 3 ). As this study is to our knowledge, the first to systematically screen by In order to determine whether there was a driver role among any of the four mutations altering promoter activity in COLO-829, we examined other cutaneous melanoma samples to identify recurrence -a key characteristic of driver mutations. Using the mutation calls from the 34 melanoma whole genomes available in the TCGA, we found that only the NDUFB9 promoter mutation was recurrent (2/34 samples). Since mutation calls at promoter regions can often be made from whole-exome sequence data, as sequencing reads frequently span up to 100 bp past intended capture regions (36), we further examined whole-exome sequencing data from cutaneous melanoma samples from the TCGA. We found that the four candidate promoter mutation sites were covered to varying extents (Table S4 ). The sequencing data revealed that the NDUFB9 promoter mutation was still the only mutation that was recurrent across other cutaneous melanomas, present in 4.4% of all samples (19/432; Table S4 ).
Owing to its recurrence, the NDUFB9 promoter mutation (chr8:125,551,344 C>T) was investigated in more detail to determine whether there was further evidence for a driver role in melanoma. The protein encoded by NDUFB9 is part of both the mitochondrial dysfunction and oxidative phosphorylation (OXPHOS) key canonical pathways. In reporter assays, activity of the mutant NDUFB9 promoter decreased compared to wild-type ( Figure   3 ). This is consistent with bioinformatic analysis that revealed that the mutation removes an SP1/Krüppel-like factor (KLF) binding motif ( Figure 4a ) and lies in a highly conserved region (Figure 4b ). SP1 is a ubiquitously expressed transcription factor that binds to GC-rich regions of many promoters (37) . Although no SP1 ChIP-seq data was available for COLO-829 or melanocytes, examination of SP1 ChIP-seq data in the HCT116 colorectal cancer cellline shows a clear peak at the promoter of NDUFB9 (Figure 4a ). As this promoter mutation substitutes a highly conserved cytosine to thymine, it is highly plausible that this mutation would result in a reduction in SP1 binding at the NDUFB9 promoter, accounting for the decrease observed in mutant promoter activity in reporter assays (Figure 3) . 
To establish the effect of the mutation within the context of melanoma samples, TCGA RNA-sequencing data were analysed. However, we found that there was no significant difference in NDUFB9 gene expression between wild-type and mutant cohorts (Figure 4c) . Nevertheless, the mutation does co-occur significantly in melanoma with nonsilent NF1 coding mutations (Figure 4d ). Co-occurrence with promoter mutations has previously been observed, with TERT and DPH3 promoter mutations both significantly cooccurring with NF1 and BRAF mutations respectively (14) . NF1 mutations are common in melanoma, resulting in the deregulation of extracellular signalling kinase pathways (38) and have been shown to be a key mediator of BRAF inhibitor resistance (39) . Coding mutations of NF1 appear to play a role in the down-regulation of NDUFB9 expression, with co-operative mutation of the NDUFB9 promoter showing the greatest decrease in NDUFB9 expression (Figures S4a and S4b) . However, NDUFB9 expression does not appear to significantly correlate with patient survival (p=0.18; Figure S4c) , meaning that the impact of the downregulation of NDUFB9 requires further investigation. However, there is some evidence that NDUFB9 is up-regulated in response to UVA damage (40) and therefore it may be possible that down-regulation of NDUFB9, via co-operative mutation of its promoter and NF1, is a first step in increasing the sensitivity of melanocytes to UV damage.
Concluding remarks
In summary, we found that promoter mutations are common in melanoma, with functionally relevant somatic mutations that alter promoter activity potentially arising quite frequently. We identified four somatic mutations within the COLO-829 cell-line that altered promoter activity when tested in these cells. One such mutation is a recurrent mutation in the NDUFB9 promoter region which may potentially play a role in melanoma development through a compound mutational pattern involving NF1. This study is the first of its kind to comprehensively survey somatic promoter mutations in a melanoma genome. By validating 
the functional consequence of each mutation experimentally in an unbiased manner, we have also evaluated the use of existing bioinformatics tools to prioritise functional non-coding mutations. The findings of this study provide a foundation for future work into evaluating the clinical significance of promoter mutations in human cancers. 
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Choi Mutations with changes in promoter activity from wild-type, as determined by reporter assays (see Figure 3) , are shaded in light grey. b DHS = DNase I hypersensitive; Y = yes. Conservation is denoted when the PhastCons conservation score (29) for the 15 bp region (mut +/-7 bp) is greater than that of the DHS region as a whole (~150 bp).
c Transcription factor motif alterations were determined by using the OncoCis tool (15) which utilises transcription factor motifs generated by the JASPAR database (30 Tracks from outside to inside are: chromosomes; regions of loss of heterozygosity (green) and complete loss of all chromosomes (grey); copy number, with <2=grey, 2=black, >2=brown; relative number of somatic mutations per megabase, with grey bars marking centromeres; heat map indicating regions of comparatively high (red) and low (green) mutation counts; putative promoter regions (blue), identified as described in Figure 1a . Lines through the circle indicate COLO-829 putative promoter mutations. Each putative promoter mutation is labelled with the associated nearest gene (bold) or genes (not bold, adjacent labels) with a transcription start site within +/-1 kb of the mutation. Each mutation has two associated spots -the outer spot indicates if the mutation is conserved (orange) or not (black) and the inner spot indicates whether at least one transcription factor motif is created or destroyed by the mutation (green) or not (grey). Copy number and regions of loss of heterozygosity were identified from previous research (19) . Representative results from one luciferase reporter assay experiment for each reporter construct tested. Results from wild-type (wt) and mutant (mt) constructs are adjacent, labelled according to the gene to which the promoter region is associated. Fold change is calculated against the average of replicate wt values. Promoter regions with no activity (luciferase activity < 2 times that of the promoter-less vector pGL2 Basic) are indicated by a cross. Only statistically significant differences (by unpaired t-test) are indicated, where * denotes p<0.05, ** denotes p<0.01 and *** denotes p<0.001. 
